Acrux licensed an AB-rated generic version of EMLA® Cream (lidocaine 2.5% and prilocaine 2.5%) to Padagis. It was launched in the United States in December 2022.
Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on:
• normal intact skin for local analgesia.
• genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.